Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have been given a consensus rating of “Moderate Buy” by the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $4.1875.

LUCD has been the subject of several recent research reports. Maxim Group decreased their target price on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a report on Friday, May 15th. Finally, Wall Street Zen raised shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday.

Key Lucid Diagnostics News

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Ascendiant Capital Markets reiterated a Buy rating and $9.25 price target on Lucid Diagnostics, while also nudging several future EPS estimates higher. The firm raised forecasts for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027 and FY2027, suggesting improved operating expectations ahead. Ascendiant Capital Markets research note
• Positive Sentiment: Another research update from Ascendiant modestly improved earnings estimates for Q2 2027 and FY2027, reinforcing a more constructive long-term view on Lucid Diagnostics (LUCD). Ascendiant Capital Markets research note
• Neutral Sentiment: Recent coverage highlighted “momentum amid cash strain,” which points to improving business traction but also reminds investors that the company still faces financing and liquidity concerns. Lucid Diagnostics’ Earnings Call: Momentum Amid Cash Strain
• Negative Sentiment: Wall Street Zen downgraded Lucid Diagnostics to Hold, which may have weighed on sentiment despite the upgraded price target from Ascendiant. Wall Street Zen Upgrades Lucid Diagnostics to Hold
• Negative Sentiment: Ascendiant also trimmed its FY2026 EPS estimate to ($0.23) from ($0.22), underscoring that Lucid is still expected to post losses over the next several years. Ascendiant Capital Markets research note

Insider Activity

In other news, Director Dennis Matheis acquired 245,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $1.00 per share, with a total value of $245,000.00. Following the acquisition, the director owned 1,033,443 shares in the company, valued at approximately $1,033,443. This represents a 31.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.80% of the company’s stock.

Institutional Trading of Lucid Diagnostics

Large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC bought a new position in Lucid Diagnostics in the first quarter valued at approximately $39,000. Goldman Sachs Group Inc. lifted its stake in Lucid Diagnostics by 35.7% in the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after buying an additional 22,727 shares in the last quarter. Geode Capital Management LLC lifted its stake in Lucid Diagnostics by 420.3% in the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock valued at $1,814,000 after buying an additional 1,274,194 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Lucid Diagnostics by 71,026.1% in the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after buying an additional 32,672 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new position in Lucid Diagnostics in the second quarter valued at approximately $97,000. 74.01% of the stock is owned by institutional investors.

Lucid Diagnostics Stock Down 1.8%

LUCD stock opened at $0.96 on Friday. The company has a market capitalization of $195.09 million, a price-to-earnings ratio of -2.04 and a beta of 1.08. Lucid Diagnostics has a 12 month low of $0.90 and a 12 month high of $1.63. The firm has a 50 day moving average of $1.09 and a two-hundred day moving average of $1.17.

Lucid Diagnostics (NASDAQ:LUCD) last posted its earnings results on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.38 million. On average, research analysts expect that Lucid Diagnostics will post -0.23 EPS for the current fiscal year.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.